The therapeutic benefits of intravenously administrated nanoparticles in stroke and age-related neurodegenerative diseases

• Published in: Current pharmaceutical design
• Main Authors: Farhoudi, Mehdi, Sadigh-Eteghad, Saeed, Mahmoudi, Javad, Farjami, Afsaneh, Mahmoudian, Mohammad, Salatin, Sara
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.07.2022
• Subjects: blood-brain barrier; nanoparticles; Alzheimer’s disease; stroke; Parkinson’s disease; Central nervous system
• DOI: 10.2174/1381612828666220608093639

The mean global lifetime risk of neurological disorders such as stroke, Alzheimer's disease (AD), and Parkinson's disease (PD) has shown a large effect on economy and society.Researchersare stillstruggling to find effective drugs to treatneurological disordersand drug delivery through the blood-brain barrier (BBB) is a major challenge to be overcome. The BBB is a specialized multicellular barrier between the peripheral blood circulation and the neural tissue. Unique and selective features of the BBB allow it to tightly control brain homeostasis as well as the movement of ions and molecules. Failure in maintaining any of these substances causes BBB breakdown and subsequently enhances neuroinflammation and neurodegeneration.BBB disruption is evident in many neurologicalconditions.Nevertheless, the majority of currently available therapies have tremendous problems for drug delivery into the impaired brain. Nanoparticle (NP)-mediated drug delivery has been considered as a profound substitute to solve this problem. NPs are colloidal systems with a size range of 1-1000 nm whichcan encapsulate therapeutic payloads, improve drug passage across the BBB, and target specific brain areas in neurodegenerative/ischemic diseases. A wide variety of NPs has been displayed for the efficient brain delivery of therapeutics via intravenous administration, especially when their surfaces are coated with targeting moieties. Here, we discuss recent advances in the development of NP-based therapeutics for the treatment of stroke, PD, and AD as well as the factors affecting their efficacy after systemic administration.